CD8A and neoplasm: A phase I clinical study showed that LTX-315 converts immunogenically “cold” tumors to “hot” in patients with advanced or metastatic tumors (melanoma, sarcoma, or breast cancer), with increases in CD8+ tumor-infiltrating lymphocytes (TILs) in more than 80% of the patients and regression of distant tumor in some individuals (15).